NCOG-25. SINGLE-INSTITUTION SERIES OF SPINAL EPENDYMOMA IN CHILDREN WITH NF2-RELATED SCHWANNOMATOSIS

Abstract NF2-related schwannomatosis (NrS) is a tumor predisposition syndrome that results in the development of multiple central nervous system tumors, including spinal ependymomas (SP-EPN). SP-EPN are intramedullary tumors that are slow growing but can displace critical nerve pathways in the spina...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro-oncology (Charlottesville, Va.) Va.), 2023-11, Vol.25 (Supplement_5), p.v219-v219
Hauptverfasser: Burket, Noah, Koenig, Jenna, Tailor, Jignesh
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page v219
container_issue Supplement_5
container_start_page v219
container_title Neuro-oncology (Charlottesville, Va.)
container_volume 25
creator Burket, Noah
Koenig, Jenna
Tailor, Jignesh
description Abstract NF2-related schwannomatosis (NrS) is a tumor predisposition syndrome that results in the development of multiple central nervous system tumors, including spinal ependymomas (SP-EPN). SP-EPN are intramedullary tumors that are slow growing but can displace critical nerve pathways in the spinal cord, resulting in motor and sensory deficits that contribute to patient morbidity. Although surgery is the mainstay of treatment, it can also result in high morbidity, resection of sporadic SP-EPN is often curative; however, SP-EPN in NrS patients will often regrow, possibly resulting in additional surgeries and a lifetime of deficits, especially impacting pediatric patients. Yet, natural history and clinical outcomes for pediatric NrS patients with SP-EPN have not been well described. We reviewed 27 pediatric NrS patient cases from 1993 to 2023 at our institution and identified 10 patients with a diagnosis of SP-EPN, with a range of 1-3 tumors present at patient diagnosis. Demographic, clinical, pathologic, and radiologic data were collected from electronic medical records. Median age of diagnosis of NrS was 12 years old (range: 5-17) and median time from NrS diagnosis to SP-EPN diagnosis was 31 days (range: -1-1636). 14 out of 16 (87.5%) initial tumors were in the cervical spine region, with C2 being the most frequently involved level. Two patients underwent resection of their tumors, with both experiencing progression of their disease and one developing paraplegia. The most common symptoms from SP-EPN were pain (30%), motor deficits (30%), and sensory deficits (30%). 40% of the patients had progressive disease at last follow up, with median time from diagnosis to progression of 3.33 years. Median time from SP-EPN to last follow-up was 4.08 years. This series showcases the burden of SP-EPN in pediatric NrS patients, emphasizing the need for further exploration into clinical outcomes and novel treatments for this debilitating condition.
doi_str_mv 10.1093/neuonc/noad179.0838
format Article
fullrecord <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10639672</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/neuonc/noad179.0838</oup_id><sourcerecordid>10.1093/neuonc/noad179.0838</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1848-ed6eeebea994b113eb18451c825cf0402ed9c49c909f398a3d69fa5e7a9e95623</originalsourceid><addsrcrecordid>eNqNkNFOgzAUhonRxDl9Am_6AsyW0kKvDGHdaMLKsrIsXjUFis5ssIAz8e3dZDHxzqtzcv7z_Ref4zwiOEGQ4afGHtumfGpaU6GATWCIwytnhIiHXRJSev2ze25IUHDr3PX9O4QeIhSNnErG2dz1yAQoIecpd4VUucjXucgkUHwluALZDKilkFEK-JLL6csiW0RASBAnIp2uuAQbkSdAzjx3xdMo51Og4mQTSXn6yzMl1L1zU5tdbx8uc-ysZzyPEzfN5iKOUrdEoR-6tqLW2sIaxvwCIWyL05mgMvRIWUMferZipc9KBlmNWWhwRVltiA0Ms4xQD4-d56H3cCz2tipt89GZnT50273pvnRrtvpv0mzf9Gv7qRGkmNHg3ICHhrJr-76z9S-MoD6r1oNqfVGtz6pP1GSg2uPhX8A35p19_w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>NCOG-25. SINGLE-INSTITUTION SERIES OF SPINAL EPENDYMOMA IN CHILDREN WITH NF2-RELATED SCHWANNOMATOSIS</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Burket, Noah ; Koenig, Jenna ; Tailor, Jignesh</creator><creatorcontrib>Burket, Noah ; Koenig, Jenna ; Tailor, Jignesh</creatorcontrib><description>Abstract NF2-related schwannomatosis (NrS) is a tumor predisposition syndrome that results in the development of multiple central nervous system tumors, including spinal ependymomas (SP-EPN). SP-EPN are intramedullary tumors that are slow growing but can displace critical nerve pathways in the spinal cord, resulting in motor and sensory deficits that contribute to patient morbidity. Although surgery is the mainstay of treatment, it can also result in high morbidity, resection of sporadic SP-EPN is often curative; however, SP-EPN in NrS patients will often regrow, possibly resulting in additional surgeries and a lifetime of deficits, especially impacting pediatric patients. Yet, natural history and clinical outcomes for pediatric NrS patients with SP-EPN have not been well described. We reviewed 27 pediatric NrS patient cases from 1993 to 2023 at our institution and identified 10 patients with a diagnosis of SP-EPN, with a range of 1-3 tumors present at patient diagnosis. Demographic, clinical, pathologic, and radiologic data were collected from electronic medical records. Median age of diagnosis of NrS was 12 years old (range: 5-17) and median time from NrS diagnosis to SP-EPN diagnosis was 31 days (range: -1-1636). 14 out of 16 (87.5%) initial tumors were in the cervical spine region, with C2 being the most frequently involved level. Two patients underwent resection of their tumors, with both experiencing progression of their disease and one developing paraplegia. The most common symptoms from SP-EPN were pain (30%), motor deficits (30%), and sensory deficits (30%). 40% of the patients had progressive disease at last follow up, with median time from diagnosis to progression of 3.33 years. Median time from SP-EPN to last follow-up was 4.08 years. This series showcases the burden of SP-EPN in pediatric NrS patients, emphasizing the need for further exploration into clinical outcomes and novel treatments for this debilitating condition.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noad179.0838</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Outcome Measures and Neuro-Cognitive Outcomes</subject><ispartof>Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v219-v219</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10639672/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10639672/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Burket, Noah</creatorcontrib><creatorcontrib>Koenig, Jenna</creatorcontrib><creatorcontrib>Tailor, Jignesh</creatorcontrib><title>NCOG-25. SINGLE-INSTITUTION SERIES OF SPINAL EPENDYMOMA IN CHILDREN WITH NF2-RELATED SCHWANNOMATOSIS</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>Abstract NF2-related schwannomatosis (NrS) is a tumor predisposition syndrome that results in the development of multiple central nervous system tumors, including spinal ependymomas (SP-EPN). SP-EPN are intramedullary tumors that are slow growing but can displace critical nerve pathways in the spinal cord, resulting in motor and sensory deficits that contribute to patient morbidity. Although surgery is the mainstay of treatment, it can also result in high morbidity, resection of sporadic SP-EPN is often curative; however, SP-EPN in NrS patients will often regrow, possibly resulting in additional surgeries and a lifetime of deficits, especially impacting pediatric patients. Yet, natural history and clinical outcomes for pediatric NrS patients with SP-EPN have not been well described. We reviewed 27 pediatric NrS patient cases from 1993 to 2023 at our institution and identified 10 patients with a diagnosis of SP-EPN, with a range of 1-3 tumors present at patient diagnosis. Demographic, clinical, pathologic, and radiologic data were collected from electronic medical records. Median age of diagnosis of NrS was 12 years old (range: 5-17) and median time from NrS diagnosis to SP-EPN diagnosis was 31 days (range: -1-1636). 14 out of 16 (87.5%) initial tumors were in the cervical spine region, with C2 being the most frequently involved level. Two patients underwent resection of their tumors, with both experiencing progression of their disease and one developing paraplegia. The most common symptoms from SP-EPN were pain (30%), motor deficits (30%), and sensory deficits (30%). 40% of the patients had progressive disease at last follow up, with median time from diagnosis to progression of 3.33 years. Median time from SP-EPN to last follow-up was 4.08 years. This series showcases the burden of SP-EPN in pediatric NrS patients, emphasizing the need for further exploration into clinical outcomes and novel treatments for this debilitating condition.</description><subject>Outcome Measures and Neuro-Cognitive Outcomes</subject><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqNkNFOgzAUhonRxDl9Am_6AsyW0kKvDGHdaMLKsrIsXjUFis5ssIAz8e3dZDHxzqtzcv7z_Ref4zwiOEGQ4afGHtumfGpaU6GATWCIwytnhIiHXRJSev2ze25IUHDr3PX9O4QeIhSNnErG2dz1yAQoIecpd4VUucjXucgkUHwluALZDKilkFEK-JLL6csiW0RASBAnIp2uuAQbkSdAzjx3xdMo51Og4mQTSXn6yzMl1L1zU5tdbx8uc-ysZzyPEzfN5iKOUrdEoR-6tqLW2sIaxvwCIWyL05mgMvRIWUMferZipc9KBlmNWWhwRVltiA0Ms4xQD4-d56H3cCz2tipt89GZnT50273pvnRrtvpv0mzf9Gv7qRGkmNHg3ICHhrJr-76z9S-MoD6r1oNqfVGtz6pP1GSg2uPhX8A35p19_w</recordid><startdate>20231110</startdate><enddate>20231110</enddate><creator>Burket, Noah</creator><creator>Koenig, Jenna</creator><creator>Tailor, Jignesh</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20231110</creationdate><title>NCOG-25. SINGLE-INSTITUTION SERIES OF SPINAL EPENDYMOMA IN CHILDREN WITH NF2-RELATED SCHWANNOMATOSIS</title><author>Burket, Noah ; Koenig, Jenna ; Tailor, Jignesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1848-ed6eeebea994b113eb18451c825cf0402ed9c49c909f398a3d69fa5e7a9e95623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Outcome Measures and Neuro-Cognitive Outcomes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Burket, Noah</creatorcontrib><creatorcontrib>Koenig, Jenna</creatorcontrib><creatorcontrib>Tailor, Jignesh</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burket, Noah</au><au>Koenig, Jenna</au><au>Tailor, Jignesh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NCOG-25. SINGLE-INSTITUTION SERIES OF SPINAL EPENDYMOMA IN CHILDREN WITH NF2-RELATED SCHWANNOMATOSIS</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2023-11-10</date><risdate>2023</risdate><volume>25</volume><issue>Supplement_5</issue><spage>v219</spage><epage>v219</epage><pages>v219-v219</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Abstract NF2-related schwannomatosis (NrS) is a tumor predisposition syndrome that results in the development of multiple central nervous system tumors, including spinal ependymomas (SP-EPN). SP-EPN are intramedullary tumors that are slow growing but can displace critical nerve pathways in the spinal cord, resulting in motor and sensory deficits that contribute to patient morbidity. Although surgery is the mainstay of treatment, it can also result in high morbidity, resection of sporadic SP-EPN is often curative; however, SP-EPN in NrS patients will often regrow, possibly resulting in additional surgeries and a lifetime of deficits, especially impacting pediatric patients. Yet, natural history and clinical outcomes for pediatric NrS patients with SP-EPN have not been well described. We reviewed 27 pediatric NrS patient cases from 1993 to 2023 at our institution and identified 10 patients with a diagnosis of SP-EPN, with a range of 1-3 tumors present at patient diagnosis. Demographic, clinical, pathologic, and radiologic data were collected from electronic medical records. Median age of diagnosis of NrS was 12 years old (range: 5-17) and median time from NrS diagnosis to SP-EPN diagnosis was 31 days (range: -1-1636). 14 out of 16 (87.5%) initial tumors were in the cervical spine region, with C2 being the most frequently involved level. Two patients underwent resection of their tumors, with both experiencing progression of their disease and one developing paraplegia. The most common symptoms from SP-EPN were pain (30%), motor deficits (30%), and sensory deficits (30%). 40% of the patients had progressive disease at last follow up, with median time from diagnosis to progression of 3.33 years. Median time from SP-EPN to last follow-up was 4.08 years. This series showcases the burden of SP-EPN in pediatric NrS patients, emphasizing the need for further exploration into clinical outcomes and novel treatments for this debilitating condition.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/noad179.0838</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v219-v219
issn 1522-8517
1523-5866
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10639672
source Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Outcome Measures and Neuro-Cognitive Outcomes
title NCOG-25. SINGLE-INSTITUTION SERIES OF SPINAL EPENDYMOMA IN CHILDREN WITH NF2-RELATED SCHWANNOMATOSIS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T18%3A37%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NCOG-25.%20SINGLE-INSTITUTION%20SERIES%20OF%20SPINAL%20EPENDYMOMA%20IN%20CHILDREN%20WITH%20NF2-RELATED%20SCHWANNOMATOSIS&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Burket,%20Noah&rft.date=2023-11-10&rft.volume=25&rft.issue=Supplement_5&rft.spage=v219&rft.epage=v219&rft.pages=v219-v219&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noad179.0838&rft_dat=%3Coup_pubme%3E10.1093/neuonc/noad179.0838%3C/oup_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/neuonc/noad179.0838&rfr_iscdi=true